Followers | 514 |
Posts | 38725 |
Boards Moderated | 5 |
Alias Born | 04/26/2012 |
Tuesday, January 22, 2019 6:03:12 PM
Source: GlobeNewswire Inc.
Summit Therapeutics plc
(‘Summit’ or the ’Company’)
Surrender of Share Options
Oxford, UK, and Cambridge, MA, US, 8 October 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that UK-based Executive Director and PDMRs, and employees have voluntarily surrendered options to subscribe for a total of 5,532,461 of the Company’s ordinary shares of one penny nominal value. Following the surrender, the total number of share options which remains outstanding is 3,073,330 (representing 3.7% of the Company’s issued share capital). The surrendered options all have exercise prices in excess of 105p. The changes to Executive Director and PDMR option holdings are summarised in the following table:
Name Position Number of share options surrendered Number of share options still held
Glyn Edwards Chief Executive Officer 3,055,096 409,959
David Roblin Chief Operating Officer and President of R&D 666,208 100,000
The Company’s remuneration policy, last approved by shareholders in July 2017, has been effective in attracting and retaining talent within the business as well as aligning the long-term interests of Executive Directors and employees with those of shareholders. The majority of the share options held by employees are significantly below their exercise price, due to the recent decline in the Company’s share price following its lead Duchenne muscular dystrophy candidate missing its primary and secondary endpoints in a Phase 2 clinical trial, with the consequence that they no longer represent a meaningful incentive.
Summit is now focussed on creating a successful antibiotics business. Its strategy is developing new mechanism antibiotics to become the new standards of care with this activity spearheaded by its Phase 3 ready antibiotic candidate ridinilazole and supported by its proprietary Discuva Platform.
In light of these developments, Summit’s Board of Directors is actively looking at ways to re-align the interests of all its employees as it seeks to deliver its business strategy and create value for shareholders. One potential method is to make a new award of share options to all employees on terms and performance conditions which reflect the current business strategy, provide the persons charged with executing that strategy with meaningful and targeted incentives, and better align their interests with those of shareholders. For this to be viable, the Company would need to increase the size of its available option pool to avoid exceeding the limit within Company policy on its ability to issue shares in the form of share options. This surrender of share options has increased the size of the option pool. The surrender will have a non-cash impact on the Company financial statements.
The Remuneration Committee of the Board of Directors continues to evaluate the choices available to it and has not as yet made any decisions or commitments with regard to the granting of new share options.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR).
Contacts
Summit Therapeutics
Glyn Edwards / Richard Pye (UK office) Tel: +44 (0)1235 443 951
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
Summit Forward-looking Statements
Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the impact of share option surrenders on the Company’s financial statements, the clinical and preclinical development of the Company’s product candidates, the therapeutic potential of the Company’s product candidates, the potential of the Discuva Platform, the potential commercialisation of the Company’s product candidates, the sufficiency of the Company’s cash resources, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, laws and regulations affecting government contracts, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that the Company makes with the Securities and Exchange Commission, including the Company’s Annual Report on Form 20-F for the fiscal year ended 31 January 2018. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.
-END-
Summit Master_rgb_png.png
:)
All my posts are my opinion only. Please do your due diligence on all your investments.
Recent SMMT News
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 09/19/2024 09:28:00 PM
- Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024 • Business Wire • 09/16/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 10:49:52 AM
- Summit Therapeutics Raises $235 Million • Business Wire • 09/12/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 11:23:04 AM
- Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China • Business Wire • 09/08/2024 03:45:00 PM
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 09/06/2024 08:15:00 PM
- HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024 • Business Wire • 08/12/2024 11:00:00 AM
- Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024 • PR Newswire (US) • 08/11/2024 11:30:00 PM
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 08/09/2024 08:15:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 08/06/2024 01:03:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 11:37:21 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 11:14:08 AM
- Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024 • Business Wire • 08/06/2024 11:00:00 AM
- Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024 • Business Wire • 07/29/2024 08:15:00 PM
- Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab • Business Wire • 07/25/2024 12:00:00 PM
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 07/03/2024 08:15:00 PM
- Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors • Business Wire • 06/27/2024 08:15:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 06/18/2024 09:14:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 09:25:01 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/13/2024 06:03:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 10:18:31 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 10:05:37 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM